Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
MT-1 is highly specific to the MC1R receptor
August Aug 30: Outlook Therapeutics lost nearly three-quarters of its market share after the FDA declined to approve ONS-5010, an investigational ophthalmic formulation of the cancer drug bevacizumab being developed for wet age-related macular degeneration (AMD)
Avoid heavy, bulky materials that limit movement
It is non-debatable
US$ 20.32
US$ 23.08
US$ 24.77
US$ 25.65
US$ 29.68
US$ 20.91
US$ 24.14
US$ 22.73
US$ 28.09
US$ 29.96
